Congratulations to Theresa Werner, MD, Huntsman Cancer Institute (HCI) investigator and University of Utah assistant professor of medicine, who received a 2016 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). Dr. Werner serves as medical director of the HCI Clinical Trials Office and manages an extensive portfolio of cancer clinical studies.
Cancer Research Posts
Huntsman Cancer Institute (HCI) at the University of Utah participated in a national summit on the Cancer Moonshot initiative on June 29, 2016. The Cancer Moonshot Summits were organized at the request of Vice President Joe Biden, and more than 270 organizations hosted summits that brought together patients and survivors, researchers, physicians, advocates, philanthropists, and data and technology experts to brainstorm ways of speeding up progress in cancer prevention, diagnosis, treatment, and care over the next five years—and to ultimately end cancer as we know it.
The Cancer Moonshot Initiative, launched during President Barack Obama’s 2016 State of the Union address and headed by Vice President Joe Biden, is generating excitement and hope in the world of cancer research and care. Huntsman Cancer Institute (HCI) at the University of Utah is playing an important role in these efforts. In addition to hosting a visit by Vice President Biden in February of this year, HCI researchers have continued to accelerate cancer research progress.
You might not see us during your visit to Huntsman Cancer Institute (HCI), but we want to let you know that we are working hard in the Varley Lab in the HCI research building next door. We conduct research that improves the treatment and care of patients like you. We are a small group of dedicated young men and women who are developing new strategies to diagnose and treat breast and ovarian cancer.
For National Cancer Control Month, Bridget Grahmann, BS, and Yelena Wu, PhD, of The Wu Team at Huntsman Cancer Institute (HCI) explain what cancer control is and how it helps people with cancer as well as those who may never have it.
Clinical trials for some cancer patients may be the last, best hope for survival. A phase I trial is the first time a treatment is studied in people—usually a select number of patients who have not had success with other treatments. A rigorous process of approval takes place before doctors test these new therapies on patients for the first time.
Inheriting a mutation in the APC gene leads to a nearly 100% lifetime risk of colorectal cancer. While colon cancer can be kept at bay by removing the large intestine, these patients also have up to a 15% risk of getting cancer in the small intestine, which is the leading cause of cancer death in this patient group. A new study published in the Journal of the American Medical Association (JAMA) has identified the first prevention treatment for these patients, a two-drug combination that significantly reduces the number and size of precancerous polyps in the small intestine.
Research by Huntsman Cancer Institute (HCI) investigators and colleagues found a decreased risk of endometrial cancer for coffee intake, and a decreased risk of cancer overall with tea intake. The findings were published in the British Journal of Cancer.
Have you ever wondered what research happens at Huntsman Cancer Institute (HCI) below the Point restaurant? Hundreds of researchers are working together every day to learn more about cancer and find better ways to support patients and families.